Onconova Therapeutics Inc (NASDAQ:ONTX) is set to announce its earnings results before the market opens on Monday, August 14th. Analysts expect the company to announce earnings of ($0.73) per share for the quarter.
Onconova Therapeutics (NASDAQ:ONTX) last announced its earnings results on Monday, May 15th. The biopharmaceutical company reported ($1.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.96) by $0.27. The business had revenue of $0.21 million during the quarter. Onconova Therapeutics had a negative return on equity of 8,850.70% and a negative net margin of 3,971.91%. On average, analysts expect Onconova Therapeutics to post $-3.29 EPS for the current fiscal year and $-2.20 EPS for the next fiscal year.
Onconova Therapeutics Inc (NASDAQ ONTX) opened at 1.92 on Friday. Onconova Therapeutics Inc has a 52 week low of $1.78 and a 52 week high of $4.12. The company’s market capitalization is $18.22 million. The firm has a 50-day moving average price of $2.05 and a 200-day moving average price of $2.38.
A hedge fund recently raised its stake in Onconova Therapeutics stock. Vanguard Group Inc. raised its position in shares of Onconova Therapeutics Inc (NASDAQ:ONTX) by 58.4% during the second quarter, according to its most recent filing with the SEC. The fund owned 87,940 shares of the biopharmaceutical company’s stock after buying an additional 32,418 shares during the period. Vanguard Group Inc. owned 0.93% of Onconova Therapeutics worth $190,000 as of its most recent SEC filing. 15.45% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Onconova Therapeutics Inc (NASDAQ:ONTX) Scheduled to Post Quarterly Earnings on Monday” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.com-unik.info/2017/08/12/onconova-therapeutics-inc-nasdaqontx-scheduled-to-post-quarterly-earnings-on-monday.html.
A number of equities research analysts have commented on ONTX shares. Laidlaw started coverage on Onconova Therapeutics in a report on Thursday, April 27th. They set a “buy” rating and a $10.00 price target on the stock. Maxim Group set a $6.00 price target on Onconova Therapeutics and gave the company a “buy” rating in a report on Tuesday, June 6th. Finally, Dawson James reissued a “buy” rating on shares of Onconova Therapeutics in a report on Tuesday, July 25th.
About Onconova Therapeutics
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.
What are top analysts saying about Onconova Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Onconova Therapeutics Inc and related companies.